PH10 (drug)
PH10 is a vomeropherine that is under development by Pherin Pharmaceuticals as a nasal spray for the treatment of major depressive disorder.[1][2] In a small phase II clinical study, PH10 demonstrated rapid antidepressant effects, taking effect by 1 week (the first scheduled assessment; future studies will check to see if the antidepressant effects onset even sooner).[1][2] In addition, the effect sizes were found to be quite large (Cohen’s d value of 1.01 for high-dose PH10 and placebo, and Cohen’s d value of 0.71 for low-dose PH10 versus placebo).[1][2] 60–80% of patients achieved remission from depression.[1][2] PH10 was well-tolerated, with adverse effects including somnolence, nasal irritation, and headache.[1][2]
See also
- PH94B (4,16-androstadien-3β-ol; Aloradine)
References
- 1 2 3 4 5 Liebowitz, MR; Nicolini, H; Monti, L; Hanover, R (2013). "PH 10 may be a new rapidly acting intranasally administered antidepressant". American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, FL.
- 1 2 3 4 5 Jancin, Bruce (2013). "Novel intranasal antidepressant shows results after 1 week". Clinical Psychiatry News. Retrieved 13 January 2016.
External links
|
---|
| | | | | |
---|
| Non-selective | |
---|
| MAOA-selective | |
---|
| MAOB-Selective | |
---|
|
| | | | | | |
|